Quantitative Cardiovascular Magnetic Resonance Myocardial Perfusion Mapping to Assess Hyperaemic Response to Adenosine Stress

Tushar Kotecha MBChB\textsuperscript{a,b}, Juan Manuel Monteagudo MD\textsuperscript{c}, Ana Martinez-Naharro MD\textsuperscript{b,c}, , Liza Chacko MBBS\textsuperscript{b,c}, James Brown MBBS\textsuperscript{a,b}, Daniel Knight MD\textsuperscript{a,b}, Kristopher D Knott MBBS\textsuperscript{a,d}, Philip Hawkins PhD\textsuperscript{b,c}, James C Moon MD\textsuperscript{a,d}, Sven Plein PhD\textsuperscript{e}, Hui Xue PhD\textsuperscript{f}, Peter Kellman PhD\textsuperscript{f}, Tim Lockie PhD\textsuperscript{b}, Niket Patel MD\textsuperscript{a,b}, Roby Rakhit MD\textsuperscript{a,b}, Marianna Fontana PhD\textsuperscript{b,c}

\textsuperscript{a}Institute of Cardiovascular Science, University College London, UK
\textsuperscript{b}Royal Free Hospital, London, UK
\textsuperscript{c}Division of Medicine, University College London, UK
\textsuperscript{d}Barts Heart Centre, London, UK
\textsuperscript{e}Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK
\textsuperscript{f}National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, Maryland, USA

Financial Support: This study was supported by the National Amyloidosis Centre, University College London and the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Disclosures: None

Word count: 4989
Address for Correspondence:

Dr. Marianna Fontana
Department of Cardiovascular Magnetic Resonance
Royal Free Hospital
Rowland Hill Street
London. NW3 2PF, UK
Telephone: +44 20 7433 2780
Fax: +44 20 7433 2803
E-mail: m.fontana@ucl.ac.uk
ABSTRACT

Aims

Assessment of hyperaemia during adenosine stress CMR remains a clinical challenge with lack of a gold-standard non-invasive clinical marker to confirm hyperaemic response. This study aimed to validate maximum stress myocardial blood flow (SMBF) measured using quantitative perfusion mapping for assessment of hyperaemic response and compare this to clinical markers of adenosine stress.

Methods and Results

Two-hundred-and-eighteen subjects underwent adenosine stress CMR. A derivation cohort (22 volunteers) was used to identify a SMBF threshold value for hyperaemia. This was tested in a validation cohort (37 patients with suspected coronary artery disease) who underwent invasive coronary physiology assessment on the same day as CMR. A clinical cohort (159 patients) was used to compare SMBF to other physiological markers of hyperaemia (splenic switch off (SSO), heart rate response (HRR) and BP fall).

A minimum SMBF threshold of 1.43ml/g/min was derived from volunteer scans. All patients in the coronary physiology cohort demonstrated regional maximum SMBF (SMBFmax) > 1.43ml/g/min and invasive evidence of hyperaemia. Of the clinical cohort, 93% had hyperaemia defined by perfusion mapping compared to 71% using SSO and 81% using HRR. There was no difference in SMBFmax in those with or without SSO (2.58±0.89ml/g/min vs 2.54±1.04ml/g/min, p=0.84) but those with HRR had significantly
higher SMBFmax (2.66ml/g/min vs 1.86ml/g/min, p<0.001). HRR>15bpm was superior to SSO in predicting adequate increase in SMBF(AUC 0.87 vs 0.62, p<0.001).

**Conclusion**

Adenosine-induced increase in MBF is accurate for confirmation of hyperaemia during stress CMR studies and is superior to traditional, clinically used markers of adequate stress such as SSO and BP response.
KEYWORDS

Cardiovascular magnetic resonance, myocardial blood flow, hyperaemia, adenosine stress
INTRODUCTION

Stress perfusion cardiovascular magnetic resonance (CMR) is established as a validated non-invasive tool for assessment of ischaemia, with high sensitivity and specificity for detection of obstructive coronary artery disease\textsuperscript{1, 2}. The absence of inducible ischaemia carries favourable prognosis for cardiovascular mortality and morbidity\textsuperscript{3, 4}. However, it is reported that 10\% of stress perfusion studies are false-negative\textsuperscript{5}. It has been proposed that one-third of false-negative studies may be due to inadequate response to pharmacological stress resulting in failure to unmask inducible perfusion defects\textsuperscript{6}.

A commonly used pharmacological stressor is adenosine, which reliably induces maximal hyperaemia in the majority of patients\textsuperscript{7}. Most protocols suggest a fixed dose administered intravenously (typically 140mcg/kg/min for 3-5 minutes), with up-titration if there is failure to reach physiological targets such as heart rate increase >10bpm, fall in systolic blood pressure (SBP) >10mmHg and/or adenosine associated symptoms\textsuperscript{8}. However, it has recently been suggested that heart rate response (HRR) and blood pressure (BP) drop are poor surrogate markers for increase in coronary blood flow\textsuperscript{9}.

Splenic switch-off (SSO), defined as reduction in splenic signal intensity during stress due to adenosine-induced splenic vasoconstriction, has been proposed as a useful sign to assess hyperaemic response and is frequently used in clinical practice. This is based on the observation that SSO was absent in up to one-third of patients with false-negative stress CMR scans\textsuperscript{10, 11}. Whilst potentially useful, the mechanisms of SSO are not fully understood and SSO assesses the systematic response to adenosine rather the direct effect on the organ of interest, the heart.

Quantitative myocardial perfusion mapping is a novel tool for assessment of inducible ischaemia in patients with suspected coronary disease\textsuperscript{12} and may also have a role
in assessment coronary microvascular dysfunction (CMD). Left ventricular hypertrophy and cardiomyopathies where myocardial blood flow may be impaired. This dual-sequence protocol provides the ability to rapidly and quantitatively assess stress myocardial blood flow (SMBF) using perfusion maps generated and displayed in-line on the scanner within minutes. As MBF can be measured at a pixel-wise level, perfusion maps may have a role in the detection of adequate hyperaemia in response to adenosine stress.

We hypothesised that peak SMBF measured on myocardial perfusion maps could be used as a direct marker of adequate hyperaemia during adenosine stress CMR studies. The aims of this study were (1) to establish a stress MBF threshold value for hyperaemia, (2) validate this threshold using invasive markers of hyperaemia as the reference standard and (3) compare this method to other clinically used markers of hyperaemia (SSO, HRR and BP response).
METHODS

Two-hundred-and-eighteen subjects were recruited. This comprised 3 cohorts: 1) a derivation cohort of 22 healthy volunteers, to derive an MBF threshold value representative of the normal minimum increase in MBF associated with adenosine hyperaemia; 2) a validation cohort of 37 patients with suspected coronary artery disease, who underwent adenosine stress CMR and invasive coronary physiological assessment on the same day, to validate the SMBF threshold value against invasive markers of hyperaemia; 3) a clinical cohort of 159 patients undergoing clinically-indicated adenosine stress CMR to assess the presence of SMBF defined hyperaemia and other physiological markers of hyperaemia (SSO, HRR and BP fall). All participants provided written informed consent prior to inclusion in the study.

Derivation cohort: healthy volunteers

In order to identify a SMBF threshold value representative of the normal minimum increase in MBF associated with adenosine hyperaemia, a validation cohort of 22 healthy controls with no symptoms and no past history of cardiovascular disease, hypertension or diabetes were recruited. All healthy volunteers underwent adenosine stress CMR using the protocol below.

Validation cohort: coronary physiology

A “coronary physiology cohort” of 37 patients scheduled for invasive coronary angiography for investigation of angina were prospectively recruited. Participants underwent adenosine stress CMR using the below protocol prior to the invasive procedure which was performed within four hours of the CMR. Patients with previous coronary artery bypass surgery (CABG), myocardial infarction (with transmural late gadolinium enhancement), unstable symptoms (including crescendo angina, angina at rest or acute
coronary syndrome), standard contraindications to CMR or adenosine, or estimated glomerular filtration rate <30ml/min/1.73m² were excluded. During coronary angiography, adenosine was administered at the same dose as during the CMR study for the measurement of FFR in at least one vessel. The presence of hyperaemia was defined as the presence of 2 out of 3 of: (1) ventricularisation of the distal pressure waveform, (2) disappearance of the dicrotic notch on the distal waveform, (3) separation of mean aortic and distal pressures⁹.

**Clinical cohort**

To compare stress response defined by SMBF, SSO, HRR and BP response, we identified a clinical cohort of 159 adenosine stress perfusion studies performed between January 2017 and November 2018. As this group was intended to represent a population encountered in routine clinical practice, patients with prior myocardial infarction, previous PCI and previous CABG were also included. Basic demographic data were extracted from electronic patient records. Heart rate at rest and stress, and presence of adenosine-induced symptoms were recorded for all studies. BP pressure at rest and stress were recorded for 110 (69%) of cases.

**CMR Protocol**

All scans were performed using a 1.5T MR scanner (Magnetom Aera, Siemens Healthcare, Erlangen, Germany) in accordance with local protocol. Patients were asked to refrain from caffeine for at least 12 hours prior to the scan. Basal, mid-ventricular and apical short-axis perfusion images were acquired both at rest and during hyperaemia. Hyperaemia was induced using adenosine infused via a peripheral cannula at a rate of 140mcg/kg/min for 4 minutes with a further 2 minutes at 175mcg/kg/min if there was evidence of insufficient stress such as no HRR and no symptoms (the coronary physiology cohort
received a fixed dose of 140mcg/kg/min for both the CMR scan and invasive physiology assessment).

**Generation of myocardial perfusion maps**

The perfusion sequence used has been described previously\textsuperscript{13}. In brief, the sequence utilised a dual sequence approach with separate pulse sequences for the arterial input function (AIF) and myocardial tissue. Image acquisition was performed over 60 heart beats with a bolus of 0.05mmol/kg gadoterate meglumine (Dotarem, Guerbet SA, Paris, France) administered at 4ml/sec followed by a 20ml saline flush during acquisition of the perfusion sequence. The arterial input function (AIF) was calculated using the left ventricular (LV) blood pool signal which was automatically segmented from optimised low-resolution proton-density weighted images acquired in parallel with higher spatial resolution saturation recovery images used for estimating myocardial perfusion. Myocardial perfusion was calculated using an automated blood tissue exchange model\textsuperscript{14} after corrections to minimise T2* losses and for non-linearity of saturation recovery, and pixel-wise perfusion maps were automatically generated in-line and displayed on the scanner after a process of motion correction and surface-coil intensity correction.

**Invasive protocol**

Invasive coronary angiography was performed via radial arterial access. Coronary physiology measurements were obtained using a coronary PressureWire (St Jude Medical, St Paul, Minnesota) connected to a RadiAnalyzer (St Jude Medical, St Paul, Minnesota). Heparin (70iu/kg) was administered prior to coronary instrumentation. Adenosine (140mcg/kg/min) was administered via a peripheral cannula for at least two minutes and until hyperaemia was achieved. Aortic and distal pressure traces were acquired at baseline and throughout adenosine administration. Pressure traces were analysed offline.
Image analysis

**Quantitative analysis of perfusion maps:** Perfusion maps were analysed offline using Osirix MD 9.0 (Bernex, Switzerland). The endo- and epicardial borders were manually delineated for each basal, mid-ventricular and apical short-axis map. Obvious image artefacts and coronary arteries were excluded from the regions-of-interest. Using a custom-made plug-in, maps were split into 16 segments. For the healthy control cohort, the segment with the lowest SMBF was used for analysis (as the minimum expected increase in MBF in response to adenosine and in the absence of cardiovascular disease or other co-morbidities). For the coronary physiology and clinical cohorts, the segment with the maximum SMBF (SMBFmax) was used for analysis (as ischaemic segments would not demonstrate significant increase in MBF).

**Splenic switch-off:** All scans were analysed for the presence of SSO, which was graded using visual comparison of the splenic tissue contrast enhancement on the stress short-axis slice in which the spleen was seen best with the rest perfusion images of the spleen. SSO was graded as either present (i.e. clearly lower splenic enhancement compared to rest) or absent (i.e. visually similar splenic enhancement at rest and stress).

**Statistical analysis**

All continuous variables were tested for normal distribution (Shapiro-Wilk test). Normally distributed metrics are summarized by the mean±standard deviation (SD). For normally distributed variables, the unpaired Student t-test was used to compare the means between two groups and one-way analysis of variance (ANOVA) with post-hoc Bonferroni correction to compare the means of multiple groups. Proportions between groups were compared using Fisher’s exact test. Receiver-operator characteristic (ROC) curves were compared using the Delong method. The Youden index was used to identify optimal cut-offs.
to predict adequate hyperaemia defined by different methods. A p value of <0.05 was considered statistically significant. ROC analyses were performed using MedCalc 13.2.1.0 (Ostend, Belgium). All other statistical analysis was performed using IBM SPSS Statistics Version 24 (IBM, Somers, New York).

RESULTS

Baseline characteristics are presented in table 1.

Derivation of SMBF threshold to define hyperaemia

The derivation cohort comprised 22 healthy controls (17 (77%) male, mean age 45±9 years). The mean SMBF of the segments with the lowest SMBF in each subject was 2.39±0.49ml/g/min. The hyperaemic threshold for SMBF to be assessed in the test cohorts was defined as 1.96SD below the mean and was 1.43ml/g/min. Mean HRR was 27±12bpm and mean change in SBP -2±10mmHg. HRR>10bpm was present in 95% of cases and fall in SBP>10mmHg present in only 15% of cases. The spleen was visible on first-pass gadolinium images in all cases. SSO was absent in 8 (36%) of cases (Figure 1). There was no significant difference in minimum SMBF between those with and without SSO (SSO 2.51±0.49ml/g/min vs No SSO 2.17±0.43ml/g/min, p=0.12).

Validation of stress MBF threshold

The validation cohort (n=37) underwent coronary angiography with coronary physiology assessment in at least one vessel within four hours of the adenosine stress CMR. Mean age was 58±17 years and 27 (73%) were male. Eighteen patients had obstructive coronary artery disease (defined as FFR<0.80 in at least one epicardial vessel) and 19 patients had no obstructive disease. All patients were assessed to have achieved hyperaemia in the catheterization laboratory as defined by changes in the invasive pressure
trace during adenosine administration. We therefore assume that all of these patients were also adequately hyperaemic during the CMR study which was performed on the same day as the invasive assessment using the same dose of adenosine and with no medication other than intravenous heparin being administered in between the two studies.

The mean SMBFmax (the myocardial segment in each participant with the highest SMBF value) was $3.28 \pm 1.01\text{ml/g/min}$. There was no difference in SMBFmax between those with or without obstructive coronary artery disease ($3.34 \pm 1.10\text{ml/g/min}$ vs $3.23 \pm 0.95\text{ml/g/min}$, $p=0.74$). All participants demonstrated at least one myocardial segment with SMBF above the threshold of $1.43\text{ml/g/min}$.

The spleen was not visible in one case (3%) and SSO was absent in 7 (19%) of cases. There was no difference in SMBFmax between those with and without SSO (SMBFmax: SSO $3.26 \pm 0.95\text{ml/g/min}$ vs no SSO $3.32 \pm 1.40\text{ml/g/min}$, $p=0.89$) (Figure 2).

During adenosine administration, there was a significant fall in invasive aortic pressure and rise in heart rate on stress (invasive mean aortic pressure: baseline $93 \pm 12\text{mmHg}$ vs hyperaemic $84 \pm 10\text{mmHg}$, $p<0.001$; heart rate: baseline $70 \pm 12\text{bpm}$ vs $83 \pm 14\text{bpm}$, $p<0.001$).

Comparison to alternative markers in clinical practice

One hundred and fifty-nine clinically requested adenosine stress CMR scans were analysed. Mean age was $64 \pm 11$ years and 123 (72%) male. The spleen was not visible in one case (0.6%). Of the cohort, 93% had evidence of hyperaemia defined as SMBFmax $>1.43\text{ml/g/min}$ compared to 71% defined by SSO, 81% defined by HRR$>10\text{bpm}$ and 42% defined by SBP fall$>10\text{mmHg}$ (Figure 3). There was no significant difference in SMBFmax in those with or without SSO (SMBFmax: $2.58 \pm 0.89\text{ml/g/min}$ SSO vs $2.54 \pm 1.04\text{ml/g/min}$ no SSO, $p=0.84$). SMBFmax was significantly higher in those with HRR$>10\text{bpm}$ compared to
those with HRR≤10bpm (2.66±0.90ml/g/min vs 1.86±0.61ml/g/min, p<0.001). There was no
difference in SMBFmax in those with SBP fall>10mmHg compared to those with SBP
fall<10mmHg (2.46±0.72ml/g/min vs 2.57ml/g/min, p=0.52).

Eighty-nine patients (56%) had invasive coronary angiography within the six months
before or after the stress CMR scan, 26 with single-vessel disease, 22 with two-vessel
disease, 12 with three-vessel disease (3VD) and 29 with unobstructed coronaries. SMBFmax
was significantly lower in patients with 3VD compared to those with unobstructed
coronaries but there was no difference in SMBFmax between the other groups (SMBFmax:
single-vessel 2.67±0.83ml/g/min, two-vessel 2.56±0.77ml/g/min, three-vessel
1.80±1.18ml/g/min, unobstructed coronaries 2.82±1.03ml/g/min; p=0.01 for 3VD vs
unobstructed coronaries, all other comparisons non-significant). Two patients had “false
negative” CMR scans. Both of these patients had SMBF defined evidence of hyperaemia,
SSO and HRR >10bpm. In both cases, angiography revealed visually moderate disease in a
single-vessel and both vessels were borderline positive on FFR measurement suggesting
these were due to discordance between the two tests in lesions with borderline significance
rather than lack of hyperaemia. Of the 12 patients who had inadequate stress defined by
SMBFmax <1.43ml/g/min, 6 (50%) had confirmed 3VD, 1 had single-vessel disease and 2 had
unobstructed coronaries, with the remaining 3 not having invasive coronary angiography as
the CMR was reported as negative for inducible ischaemia (Figures 4 and 5). All patients
with confirmed 3VD and the one with single-vessel disease had visual perfusion defects on
first-pass perfusion. The 3 patients without angiographic data and the 2 with unobstructed
coronaries had no visual perfusion defects.

Predictors of SMBF defined hyperaemic response
Using SMBFmax > 1.43ml/g/min as the definition for adequate stress, HRR > 15 bpm was able to predict hyperaemia with sensitivity 63% and specificity 91% (AUC 0.87 (95% confidence interval 0.82-0.92), p<0.001) (Figure 6). HRR > 10 bpm had sensitivity 85% and specificity 64%. The presence of SSO had a sensitivity of 73% and specificity of 50% for the prediction of hyperaemia (AUC 0.62 (0.55-0.68), p=0.13) and was inferior to heart rate response (p<0.001). Change in BP was unable to predict hyperaemic response.
DISCUSSION

SMBF derived from pixel-wise in-line CMR myocardial perfusion maps can be used to confirm hyperaemic response during adenosine stress studies. SMBF >1.43ml/g/min in at least one myocardial segment is a robust marker of hyperaemia as confirmed by invasive coronary physiology. Our data suggests that lack of hyperaemic response is less of a clinical issue than previously reported\(^6,10,11\) with the vast majority of patients displaying increase in MBF. We therefore propose a diagnostic algorithm for the assessment of hyperaemia based upon SMBFmax and using HRR to guide up-titration of adenosine dose (Figure 7).

The confirmation of adequate hyperaemia during adenosine stress remains a clinical challenge due to lack of a “gold standard” non-invasive measure of hyperaemic response. In normal coronary arteries, intravenous adenosine infusion increases coronary blood flow velocity by greater than 4 times above resting velocity, as well as increasing heart rate by more than 20bpm and fall in BP\(^7\). These initial observations supported the clinical use of HRR and BP drop as surrogate markers for hyperaemia. However, more recent studies have shown conflicting results regarding the use of heart rate and BP as markers of adenosine hyperaemia\(^9,15\). Invasive studies demonstrate that increasing the dose of adenosine above 140mcg/kg/min fails to result in changes in FFR\(^16,17\) but there is no data on coronary flow velocity or markers of CMD. It could be hypothesised that patients with CMD may not fully respond to standard doses of adenosine, but further studies are required to clarify the role of high-dose adenosine for stress perfusion studies. Current guidelines recommend increasing doses up to 210mcg/kg/min depending upon peripheral haemodynamic response\(^8\).

Invasive measurement of coronary flow reserve with a Doppler flow wire is the reference standard for hyperaemia assessment. However, hyperaemia can also be
invasively assessed using changes in the invasive pressure wave form using the pressure traces obtained from a standard pressure wire used in routine clinical practice for FFR measurements. Whilst this method is limited by not being a direct measure of adenosine-induced increase in blood flow, it is simpler to acquire and has been validated against coronary flow reserve\textsuperscript{9}. In the present study, we demonstrate that in patients with invasive evidence of hyperaemia, SMBF was always above the 1.43ml/g/min threshold in at least one segment whilst only 81\% of patients demonstrated a HRR >10bpm, 81\% demonstrated SSO and 55\% demonstrated a SBP drop >10mmHg. Interestingly, whilst patients exhibiting HRR displayed significantly higher SMBF compared to those without, neither SSO nor BP drop were associated with higher SMBF. These data suggest that currently used surrogate markers of myocardial hyperaemia (SSO, BP fall>10mmHg and HRR >10bpm) may result in many studies being graded as non-diagnostic despite the fact that MBF has been significantly increased. The poor performance of these surrogate markers is likely due to the complexity of the systemic response to adenosine and the influence that other factors such as fluid status, co-morbidities, anxiety and use of medication.

One theoretical limitation of the SMBF based approach is the fact that patients with 3VD often have global ischaemia and therefore may not significantly increase their MBF. Interestingly, only 50\% of patients with 3VD in this cohort failed to increase their MBF above the defined threshold as even in the presence of severe epicardial disease there may be some elevation in MBF in at least one myocardial segment and predominantly on the epicardial side of the myocardium. Furthermore, all of these patients with obstructive 3VD had visual perfusion defects on first pass perfusion images and were therefore classified as positive for myocardial ischaemia. Additionally, conditions such as severe CMD and cardiomyopathies with hypertrophic phenotypes (for example hypertrophic
cardiomyopathy and cardiac amyloidosis) may also display global reductions in stress MBF below the threshold value despite adequate response to adenosine stress. The estimated prevalence of CMD is up to 50% of patients undergoing positron-emission tomography myocardial perfusion imaging for investigation of chest pain\(^\text{18}\) and two-thirds of patients with unobstructed coronaries at invasive coronary angiography\(^\text{19}\). Only 7% of our cohort failed to achieve SMBF >1.43ml/g/min, significantly lower than prevalence of CMD. This is likely due to the cut-off chosen to define hyperaemic response, which is significantly lower than the published cut-off for the identification of CMD (SMBF <2.25ml/g/min)\(^\text{20}\). Some cases of severe CMD could fail to increase SMBF >1.43ml/g/min and be falsely classified as lack of hyperaemic response. However, this is likely to represent a small proportion of patients and with both explanations for low SMBF (severe CMD or lack of hyperaemia) further clinical investigations would be indicated. We therefore suggest that SMBF >1.43ml/g/min is a reliable marker of adequate stress but a value <1.43ml/g/min does not necessarily indicate inadequate stress.

Our data suggest that HRR still has a role in the assessment of hyperaemic response as it is associated with increased SMBF. Patients with HRR >10bpm had significantly higher SMBF\text{max} than those without HRR and HRR >10bpm has reasonable sensitivity but poor specificity. ROC analysis suggests that HRR >15bpm is a better threshold with high specificity for prediction of stress MBF defined hyperaemia. We therefore propose an algorithm whereby HRR is used to guide adenosine dose increases and stress MBF used to define adequate stress.

Myocardial perfusion mapping is a simple to use sequence that delivers colour-coded pixelwise perfusion maps inline to the scanner within minutes of acquisition. MBF measured using this sequence shows good repeatability in controls with SMBF showing
better repeatability than myocardial perfusion reserve\textsuperscript{21}. Quantitative perfusion maps can be easily analysed visually and quantitatively to measure stress MBF. This can be done in real time so, if necessary, adenosine stress can be repeated with a higher dose where stress is deemed sub-maximal. For these reasons, we suggest using SMBF for assessment of hyperaemic response rather than myocardial perfusion reserve which requires the additional acquisition of rest perfusion maps.

**Limitations**

This is a small single centre study with the aim of assessing whether myocardial perfusion maps may be useful tool for the detection of hyperaemic response. A further larger multicentre study in which the actual rates of false-negative studies is assessed is required before this method can be fully implemented into clinical practice.

The threshold value of 1.43ml/g/min was derived from a cohort of healthy volunteers who were younger than typical clinical patients, predominantly male and without any comorbidities. Therefore, hyperaemic response may be different from that observed in clinical patients although our data suggest that the majority of clinical patients are able to achieve this threshold in at least one myocardial segment. The invasive method used to confirm hyperemia was a qualitative one using pressure traces rather than the gold standard measurement of coronary flow reserve using a Doppler wire, however this method has been previously validated against the reference standard\textsuperscript{9}.

We did not test for blood levels of caffeine or xanthines prior to the stress CMR studies. We obtained both verbal and written confirmation from participants that they had not consumed caffeine in the 12 hours prior to the scan.

**Conclusion**
In summary, this study demonstrates that myocardial perfusion mapping can be used to confirm adequate hyperaemic response to adenosine stress, giving clinicians additional confidence when reporting clinical stress perfusion studies. We suggest that this tool is more useful than existing markers such as SSO, HRR and BP response, and is easy to use in clinical practice.
REFERENCES


FIGURE LEGENDS

Figure 1: Stress perfusion maps, rest perfusion maps and splenic first pass perfusion of healthy controls. Examples cases with (upper panel) and without (lower panel) splenic switch off. Both cases show similar increase in myocardial blood flow (MBF).
Figure 2: Perfusion maps, first-pass perfusion and coronary angiogram of patient with obstructive coronary artery disease. Perfusion maps (A and B) and first-pass perfusion (C) show a subendocardial inducible perfusion defects in the inferior and inferolateral wall corresponding with angiographically severe stenoses in the obtuse marginal (OM) and left posterior descending artery (PDA) (E). Stress (A) and rest (B) perfusion maps show significant increase in myocardial blood flow (MBF) remote to the ischaemic area despite lack of splenic switch off (D).
Figure 3: Classification of adequate stress based on stress myocardial blood flow (MBF), splenic switch-off (SSO), heart rate response and blood pressure (BP) response. Percentage of cases defined as adequate hyperaemia based on different methods. (Hyperaemia defined as stress MBF > 1.43 ml/g/min, presence of SSO sign, heart rate increase > 10 bpm or BP fall > 10 mmHg).
Figure 4: Perfusion maps, splenic first-pass perfusion and coronary angiogram in obstructive three-vessel disease. Panel A: Global reduction of stress myocardial blood flow (MBF) with some areas of increased MBF on the epicardial side of the myocardium. Panel B: Rest perfusion map. Panel C: First-pass stress perfusion shows global subendocardial perfusion defect consistent with three-vessel disease. Panels D: Splenic switch-off. Panels E and F: Coronary angiogram showing severe obstructive three-vessel disease.
Figure 5: Perfusion maps and splenic first pass perfusion of patient with inadequate stress.

Stress perfusion map (A) shows maximum stress myocardial blood flow (MBF) below hyperaemic threshold and similar to rest MBF values (B). There is also no splenic switch-off (C).
Figure 6: Heart rate increase as a predictor of hyperaemic response. ROC curve for change in heart rate to detect hyperaemic response as defined by maximum stress myocardial blood flow (MBF) >1.43ml/g/min. A heart rate increase of >15bpm had a sensitivity of 63% and specificity of 91%.

AUC = 0.869
P < 0.001
Figure 7: Adenosine stress CMR protocol using myocardial perfusion mapping. Suggested algorithm based on heart rate response and perfusion maps. SMBFmax: maximum myocardial blood flow on stress maps.
# TABLES

## Table 1: Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Validation cohort (n=22)</th>
<th>Coronary physiology cohort (n=37)</th>
<th>Clinical cohort (n=159)</th>
<th>p-value (coronary physiology vs clinical cohort)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>45±9</td>
<td>59±17</td>
<td>64±11</td>
<td><strong>0.02</strong></td>
</tr>
<tr>
<td>Males</td>
<td>17 (77%)</td>
<td>27 (73%)</td>
<td>123 (77%)</td>
<td>0.67</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0 (0%)</td>
<td>22 (60%)</td>
<td>80 (51%)</td>
<td>0.37</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0 (0%)</td>
<td>12 (32%)</td>
<td>55 (35%)</td>
<td>0.85</td>
</tr>
<tr>
<td>Hyperlipidaemia</td>
<td>0 (0%)</td>
<td>28 (76%)</td>
<td>87 (55%)</td>
<td><strong>0.03</strong></td>
</tr>
<tr>
<td>Previous PCI</td>
<td>0 (0%)</td>
<td>2 (5.4%)</td>
<td>61 (39%)</td>
<td><strong>&lt;0.01</strong></td>
</tr>
<tr>
<td>Previous CABG</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>27 (17%)</td>
<td><strong>&lt;0.01</strong></td>
</tr>
</tbody>
</table>

Table 2: Myocardial blood flow and clinical parameters during stress perfusion studies.

<table>
<thead>
<tr>
<th></th>
<th>Control cohort (n=22)</th>
<th>Coronary physiology cohort (n=37)</th>
<th>Clinical cohort (n=159)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Myocardial blood flow</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMBFmax(ml/g/min)</td>
<td>4.10±0.99</td>
<td>3.28±1.01</td>
<td>2.57±0.93</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Resting MBF(ml/g/min)</td>
<td>0.80±0.21</td>
<td>0.93±0.27</td>
<td>1.01±0.37</td>
<td>0.03</td>
</tr>
<tr>
<td>Maximum myocardial</td>
<td>5.6±1.2</td>
<td>3.8±1.4</td>
<td>2.7±1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>perfusion reserve</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood pressure(mmHg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline systolic BP</td>
<td>122±12</td>
<td>135±28</td>
<td>136±22</td>
<td>0.03</td>
</tr>
<tr>
<td>Baseline diastolic BP</td>
<td>71±7</td>
<td>75±12</td>
<td>72±12</td>
<td>0.59</td>
</tr>
<tr>
<td>Hyperaemic systolic BP</td>
<td>120±12</td>
<td>122±24</td>
<td>127±21</td>
<td>0.30</td>
</tr>
<tr>
<td>Hyperaemic diastolic BP</td>
<td>70±8</td>
<td>66±9</td>
<td>67±14</td>
<td>0.68</td>
</tr>
<tr>
<td>Systolic BP fall</td>
<td>2±10</td>
<td>13±14</td>
<td>9±17</td>
<td>0.12</td>
</tr>
<tr>
<td>Diastolic BP fall</td>
<td>1±7</td>
<td>10±9</td>
<td>5±10</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Heart rate(bpm)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline heart rate</td>
<td>63±9</td>
<td>66±11</td>
<td>67±14</td>
<td>0.40</td>
</tr>
<tr>
<td>Hyperaemic heart rate</td>
<td>91±14</td>
<td>89±13</td>
<td>85±15</td>
<td>0.21</td>
</tr>
<tr>
<td>Heart rate increase</td>
<td>27±12</td>
<td>23±12</td>
<td>19±11</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

SMBFmax: maximum stress myocardial blood flow; BP: blood pressure; bpm: beats per minute.